The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an oral peptide targeting interleukin (IL)-23, a randomized study showed. The ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Medically reviewed by Casey Gallagher, MD A few treatments are known to help clear psoriasis symptoms fast, such as Clobex ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...

Tapinarof cream was approved in May 2022 for treatment of mild, moderate, or severe plaque psoriasis in adults. As per the pivotal PSOARING trials, “about 40% of patients on tapinarof will ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...